In a bold step toward shaping the future of healthcare, the Department of Health – Abu Dhabi (DoH) has entered into a strategic partnership with Boehringer Ingelheim, one of the world’s leading pharmaceutical companies. The agreement is set to catalyze innovation across Abu Dhabi’s life sciences ecosystem by advancing solutions in early detection, disease prevention, and population health management.
This partnership is a key pillar of Abu Dhabi’s long-term commitment to positioning itself as a global hub for healthcare innovation, biotechnology, and evidence-based patient care. It brings together two industry leaders united by a shared vision: to enable healthier communities through proactive, data-driven, and inclusive health systems.
Uniting for Public Health: From Awareness to Action
With a rising global and regional burden of non-communicable diseases—including diabetes, cardiovascular and renal conditions, pulmonary fibrosis, and stroke—this collaboration prioritizes prevention as the first line of defense. Joint initiatives will include targeted awareness campaigns, community screening programs, educational efforts to promote healthy lifestyles, and comprehensive strategies to close gaps in early detection.
A key feature of the partnership is the integration of real-world data and health analytics, which will support more accurate risk assessment, informed policy decisions, and timely interventions for at-risk populations across the Emirate.
Leadership Commitment to Building Healthier Futures
Speaking on behalf of the Department of Health, H.E. Dr. Rashed Al Suwaidi, Director General of Abu Dhabi Public Health Centre, highlighted the impact of the initiative:
“The increasing prevalence of non-communicable diseases across the globe demands decisive and united action. This collaboration reflects our unwavering commitment to population health by strengthening awareness, empowering our communities, and prioritising preventive care as a strategic imperative.”
From Boehringer Ingelheim, Ousama Alhaj, General Manager and Head of Human Pharma UAE, reaffirmed the company’s dedication to patient-centered progress:
“Meaningful transformation in healthcare is only possible through collaboration. Together with DoH, we aim to bring innovative, value-driven health solutions to life—solutions that not only treat but prevent, empower, and elevate the well-being of generations to come.”
Aligning with Abu Dhabi’s Life Sciences Vision
This partnership adds to a growing list of international collaborations forged by the Department of Health – Abu Dhabi to accelerate the local life sciences landscape. Recent alliances with global pharmaceutical and biotech giants—such as GSK, Novartis, Takeda, Eli Lilly, and AbbVie—are collectively contributing to Abu Dhabi’s emergence as a center of excellence in clinical research, personalized medicine, genomics, and digital health.
With this new partnership, DoH and Boehringer Ingelheim aim not only to address current health challenges, but also to lay the groundwork for a robust, agile, and innovation-driven healthcare system that is prepared for the future.
Next Milestones on the Horizon
In the months ahead, the collaboration will roll out a series of impactful programs, including:
Launch of integrated screening and education initiatives in local communities
Development of advanced health data platforms for chronic disease surveillance
Introduction of digital tools to enhance patient engagement and clinical decision-making
Measurable tracking of population health indicators to guide future interventions
-
-
-
-
